» Download Public Reports
14 reports
- Company report
- March 2011
- 40 pages
... Expansion of green areas generics provide for efficient (affordable) health care Sustainable, better use of resources Business model with no animal testing Image as health care ag social ...
March 2011
... To surprisingly more than expected price erosion in the few products (especially multiple player product launches) and as well increased competition in us generic market. Eventually, gross profit grew by 28 ...
March 2011
... Global generics revenues from north america: Growth was driven by new product launches of clpidogrel, otc lansoprazole and supported by its key products ziprasidone, fondaparinux, quetiapine, etc ...
March 2011
... Income statement highlights R & d expense were rs.1800 Mn about 6% of r Gross profit margin at 53.1% In q2 global generics and psai segments were at 59 Capital expenditure in q2fy13 at rs 1800 ...
March 2011
... In the us generics market remains a major concern. The management S outlook on the us market throws up a significant challenge to the company in terms of sustaining growth in the near-to-medium term ...
March 2011
... Highlights- revenues from global generics segment is at rs 191mn in q1fy13which is a yoy growth of 32% which is mainly driven by markets of north america, russia &emerging markets. Global generics ...
March 2012
... In emerging markets. Lack of new launches and price erosion in us base business. Margin contraction due to higher sg&a & r&d costs. R&d spend to be +7% aided by development of biosimilars/niche products ...
March 2011
... Registering 31.8% Yoy growth, which was higher than our estimate of `2,272cr. The global generics market registered growth of 29.9% Yoy, led by growth across the u.S. And russian markets ...
March 2011
... generics during the quarter. Company has taken ~24% of market share and price erosion was ~70% for geodon. 16 New product launches happened during fy12. Strong volume growth was contributed by new products ...
March 2012
... Emerging market territories pharmaceutical services & active ingredients Fy12 revenue mix 25% of total Amongst the leaders in supply of generic apis globally Customers include generic manufactus ...